IND/IDEC: Zevalin and Rituxan for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma (Barbara Grant, MD)
CALGB 50201: A Phase II Study to Evaluate the Safety and Efficacy of Zevalin (IND # BB IND 11023) Therapeutic Regimen in Patients with Transformed CD20+ B-cell Non-Hodgkin's Lymphoma (Barbara Grant, MD)
CALGB 10301: A Phase II Study of BORTEZOMIB (PS-341) and Pegylated Liposomal Doxorubicin as Initial Therapy for Patients with Symptomatic Multiple Myeloma (Barbara Grant, MD)
C80303: A Randomized Phase III Trial of Gemcitabine plus Bevacizumab (NSC #704865) versus Gemcitabine plus Placebo in Patients with Advanced Pancreatic Cancer (Marc Greenblatt, MD)
PARST0321: A Phase II Study of Sulindac and Tamoxifen in Patients with Desmoid Tumors that are Recurrent or Not Amenable to Standard Therapy (Alan Homans, MD)
RTOG0232: A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone for Selected Patients with Intermediate Risk Prostatic Carcinoma (Peter Swift, MD)
For more information about these studies, call Holli McFadden, Clinical Trials Office, at 802-656-2178.